Edgewise Therapeutics Inc EWTX

$37.68 -0.43 (-1.13%)

Valuation

Market cap
4,224,696,000
Revenue TTM
$0
Net income TTM
$-167,800,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,878,500
Avg volume
1,433,594
Day's range
$36.70 – $40.41
Shares out
108,604,000
Stochastic %K
16%
Beta
0.35
Analysts
Strong Buy
Price target
$52.62

Price

Company profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a...

Show more

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Industry
Biotechnology
Sector
Healthcare
Phone
720 262 7002
Website
https://edgewisetx.com
Address
1715 38th Street, Boulder, United States

Latest news

Stocktwits

Merlintrader Nov 1, 8:14 PM
$EWTX closed the week at $38.90 (-1.0% w/w), below the 50-day SMA ($41.34) and above the 200-day ($36.28). RSI14 45.7. 20-day range $35.63-$41.79. EWTX Stock Hub: Edgewise Therapeutics News, Cardiac Programs and Trials https://www.merlintrader.com/edgewise-therapeutics-stock-hub/
0 replies
SannieVerraderlijk Oct 29, 8:32 AM
Bought some goodcos with some of the SLN cash: $EWTX , $BLTE , added to $ARWR , $BBIO
0 replies
Merlintrader Oct 27, 8:30 AM
$EWTX closed Monday at $39.17, below the 50-day SMA ($41.74) and above the 200-day ($35.33), mid-way through its 20-day range ($35.63-$42.12). Daily RSI 47. Bull and bear scenarios, support/resistance and trendlines on the interactive JC Just Charts page: https://justcharts.merlintrader.com/#EWTX Not investment advice.
0 replies
Quantumup Oct 16, 10:22 AM
William Blair🏁 $EWTX and said -- We are initiating coverage of Edgewise with an Outperform rating; our DCF-adjusted valuation is $53 per share. $CYTK $BMY TECX AZN NVO BAYRY MLYS TENX Here's what William Blair had to say: https://x.com/Quantumup1/status/2111039712416637267?s=20
0 replies
Quantumup Oct 15, 8:58 PM
William Blair🏁 $CYTK and said -- We are initiating coverage of Cytokinetics with an Outperform rating, and our DCF-based valuation is $101/share. $EWTX $BMY TECX TENX AZN NVO BAYRY William Blair added—Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and its first approved product, MYQORZO. Our CYTK call: We have conviction in a strong MYQORZO launch through 2027. Around mid-2027, we model nHCM approval, assuming priority review, adding ~100K addressable patients. We estimate 2032 sales of ~$3.74B.
0 replies
Trainguy1 Oct 15, 11:42 AM
$EWTX I was just looking at Hypertrophic Cardiomyopathy in www.clinicaltrials.gov and I noticed 407 HCM studies are registered there. It just goes to show how huge the demand for HCM therapeutics is. Edgewise made a good decision to focus on HCM.
0 replies
Quantumup Oct 14, 11:12 AM
UBS⬇️ $CYTK's PT to $104, reiterated Buy and said -- We see CYTK as an attractive launch name (oHCM) that has the added benefit of diversification (nHCM) and potential removal of competitive overhang (EWTX). $EWTX $BMY TECX TENX AZN NVO BAAYRY UBS added—Similar to a number of other commercial biotech names (NBIX, AXSM, JAZZ, UTHR, INSM), CYTK has also underperformed recently as XBI pulled back. However, if interest-rate hike cycle is likely to drive further "risk-off" environment, we believe names like CYTK can outperform from current levels. In our view, Myqorzo will see continued sales inflection in 3Q which could point towards strong FY26/27 sales. Along with oHCM launch updates, we see multiple potentially positive catalysts on the horizon: 1) nHCM SNDA submission, 2) EDG-7500 Ph3 trial initiation (requiring echos); and 3) MAPLE/1L label expansion (PDUFA Nov. 14). We lower our PT to $104 (from $115), and reit our Buy rating.
0 replies
Kostcoboi Oct 11, 2:49 PM
$BMY $CYTK $EWTX $TNYA this reinforces that $TNYA’s TN-201 occupies a narrower, genetically-defined niche rather than going head-to-head with the two approved blockbuster-track drugs. which is actually a reasonable position (less direct competition for a specific patient subset) rather than a weakness. It’s also a fix to the problem rather than managing the problem like what $BMY is doing. $TNYA’s TN 201 holds EMA PRIME designation in Europe and FDA Fast Track / Rare Disease Evidence Principles engagement in the United States.
0 replies